ATE450526T1 - Als antagonisten von histamin h3 geeignete piperidinderivate - Google Patents
Als antagonisten von histamin h3 geeignete piperidinderivateInfo
- Publication number
- ATE450526T1 ATE450526T1 AT06773528T AT06773528T ATE450526T1 AT E450526 T1 ATE450526 T1 AT E450526T1 AT 06773528 T AT06773528 T AT 06773528T AT 06773528 T AT06773528 T AT 06773528T AT E450526 T1 ATE450526 T1 AT E450526T1
- Authority
- AT
- Austria
- Prior art keywords
- histamine
- antagonists
- piperidine derivatives
- derivatives suitable
- piperidine
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229960001340 histamine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69211005P | 2005-06-20 | 2005-06-20 | |
| PCT/US2006/023800 WO2007001975A1 (en) | 2005-06-20 | 2006-06-19 | Piperidine derivatives useful as histamine h3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE450526T1 true ATE450526T1 (de) | 2009-12-15 |
Family
ID=36968725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06773528T ATE450526T1 (de) | 2005-06-20 | 2006-06-19 | Als antagonisten von histamin h3 geeignete piperidinderivate |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7635705B2 (de) |
| EP (1) | EP1902046B1 (de) |
| JP (1) | JP2008546784A (de) |
| KR (1) | KR20080021082A (de) |
| CN (1) | CN101243072A (de) |
| AR (1) | AR054787A1 (de) |
| AT (1) | ATE450526T1 (de) |
| AU (1) | AU2006262441A1 (de) |
| CA (1) | CA2610959A1 (de) |
| DE (1) | DE602006010870D1 (de) |
| ES (1) | ES2337727T3 (de) |
| IL (1) | IL187984A0 (de) |
| MX (1) | MX2008000115A (de) |
| TW (1) | TW200738676A (de) |
| WO (1) | WO2007001975A1 (de) |
| ZA (1) | ZA200710968B (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| EP1965862A2 (de) * | 2005-12-21 | 2008-09-10 | Schering Corporation | Kombination aus einem h3-antagonisten/inversen agonisten und einem appetitzügler |
| TW200825072A (en) * | 2006-10-20 | 2008-06-16 | Arete Therapeutics Inc | Soluble epoxide hydrolase inhibitors |
| JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| CA2675450A1 (en) * | 2007-01-29 | 2008-08-07 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| JP2010520199A (ja) * | 2007-03-02 | 2010-06-10 | シェーリング コーポレイション | ピペリジン誘導体およびその使用方法 |
| BRPI0721451A2 (pt) * | 2007-03-13 | 2014-03-25 | Arete Therapeutics Inc | Compostos de 4-piperidiniluréia como inibidores de epóxido hidrolase solúvel |
| RS52518B (sr) | 2007-04-23 | 2013-04-30 | Janssen Pharmaceutica N.V. | Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti |
| MX2009011416A (es) | 2007-04-23 | 2009-11-05 | Janssen Pharmaceutica Nv | Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. |
| EP2141994A4 (de) * | 2007-04-26 | 2011-05-18 | Avalon Pharmaceuticals | Mehrringverbindungen und ihre verwendungen |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| CA2729313C (en) | 2008-07-03 | 2016-08-30 | Janssen Pharmaceutica Nv | Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists |
| EP2318388A2 (de) | 2008-07-23 | 2011-05-11 | Schering Corporation | Tricyclische spirocyclusderivate und verfahren zu deren verwendung |
| ES2622161T3 (es) | 2008-07-31 | 2017-07-05 | Janssen Pharmaceutica, N.V. | Piridinas sustituidas con piperazin-1-il-trifluorometilo como antagonistas del receptor de la dopamina 2 de disociación rápida |
| JP5642661B2 (ja) * | 2009-03-05 | 2014-12-17 | 塩野義製薬株式会社 | Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体 |
| US8337835B2 (en) * | 2009-04-10 | 2012-12-25 | Washington University | Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders |
| WO2011090062A1 (ja) * | 2010-01-22 | 2011-07-28 | 大鵬薬品工業株式会社 | Pgds阻害作用を有するピペラジン化合物 |
| WO2011153359A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| EP2661421A2 (de) * | 2011-01-07 | 2013-11-13 | Targacept, Inc. | Nichtkompetitive antagonisten des nikotinrezeptors |
| US8865641B2 (en) * | 2011-06-16 | 2014-10-21 | The Feinstein Institute For Medical Research | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways |
| MX360979B (es) | 2011-09-16 | 2018-11-22 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico. |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| CN102657868A (zh) * | 2012-05-30 | 2012-09-12 | 中国药科大学 | 5-羟色胺2受体拮抗剂或转运体抑制剂治疗脂肪肝或高脂血症 |
| CA2875979C (en) | 2012-06-06 | 2021-01-26 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN109082465A (zh) * | 2018-08-20 | 2018-12-25 | 苏州市广济医院 | 奥氮平诱导糖代谢紊乱相关疾病的分子标志物及其用途 |
| MA55556A (fr) | 2019-04-02 | 2022-02-09 | Aligos Therapeutics Inc | Composés ciblant prmt5 |
| WO2021187605A1 (ja) * | 2020-03-19 | 2021-09-23 | 田辺三菱製薬株式会社 | 含窒素複素環αシアノカルボニル化合物 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US661145A (en) * | 1900-08-06 | 1900-11-06 | Otto Hausmann | Attachment for bicycles. |
| US856473A (en) * | 1906-05-21 | 1907-06-11 | Daniel E Krause | Drilling-machine. |
| US4983567A (en) * | 1987-03-16 | 1991-01-08 | Biomeasure, Inc. | Immunomodulators and methods of making same |
| US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
| US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| US5688785A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| JP2525125B2 (ja) | 1991-07-23 | 1996-08-14 | シェリング・コーポレーション | 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法 |
| US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| WO1995001961A1 (en) | 1993-07-09 | 1995-01-19 | Schering Corporation | Process for the synthesis of azetidinones |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5627176A (en) | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5618707A (en) | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
| WO1997016424A1 (en) | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
| US5886171A (en) | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
| US5739321A (en) | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
| KR20000029975A (ko) | 1996-08-16 | 2000-05-25 | 둘락 노먼 씨. | 히스타민수용체길항제의배합물을사용한상부기도알레르기반응의치료 |
| US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| US6133001A (en) | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
| CA2333554A1 (en) * | 1998-06-17 | 1999-12-23 | Chu-Baio Xue | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US5919672A (en) | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
| US6207822B1 (en) | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
| AR023463A1 (es) | 1999-04-16 | 2002-09-04 | Schering Corp | Uso de compuestos de azetidinona |
| HUP0301391A3 (en) | 2000-02-11 | 2010-03-29 | Vertex Pharma | Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use |
| US20020045686A1 (en) | 2000-08-24 | 2002-04-18 | The Yokohama Rubber Co., Ltd | Rubber composition having improved wet skid resistance and rolling resistance |
| DE10042447A1 (de) | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
| PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| EP1345895B1 (de) | 2000-12-21 | 2006-12-27 | Sanofi-Aventis Deutschland GmbH | Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen |
| MXPA03005019A (es) | 2000-12-21 | 2003-09-25 | Avantis Pharma Deutschland Gmb | Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso. |
| IL156552A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| MXPA03008356A (es) | 2001-03-13 | 2003-12-11 | Schering Corp | Compuestos del tipo no imidazol como antagonistas de histamina h3. |
| DK1373230T3 (da) | 2001-03-28 | 2005-11-07 | Schering Corp | Enantiselektiv syntese af azetidinon mellemprodukter |
| US20030137689A1 (en) * | 2002-01-18 | 2003-07-24 | General Instrument Corporation. | Remote printer driver server |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| US7220735B2 (en) | 2002-04-18 | 2007-05-22 | Schering Corporation | Benzimidazolone histamine H3 antagonists |
| NZ535763A (en) | 2002-04-18 | 2007-06-29 | Schering Corp | (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists |
| DE10227507A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE10227506A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE10227508A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| IL165863A0 (en) | 2002-06-24 | 2006-01-15 | Schering Corp | Indole derivatives useful as histamine H3 antagonists |
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| EP1529061B1 (de) | 2002-08-06 | 2008-02-13 | Sanofi-Aventis Deutschland GmbH | Verfahren zur isolierung eines intestilanen cholesterin bindenproteins |
| WO2004069338A1 (en) * | 2003-01-31 | 2004-08-19 | Schering Corporation | Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| CA2517571C (en) | 2003-03-07 | 2011-07-05 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
| GB0308333D0 (en) | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| CA2523431A1 (en) | 2003-04-23 | 2004-11-25 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| US20040224952A1 (en) | 2003-05-07 | 2004-11-11 | Cowart Marlon D. | Fused bicyclic-substituted amines as histamine-3 receptor ligands |
| JP2005015434A (ja) | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
| GB0315360D0 (en) | 2003-07-01 | 2003-08-06 | Burns Robert N | Anti-theft device |
| WO2005009955A1 (en) | 2003-07-31 | 2005-02-03 | Hetero Drugs Limited | Ezetimibe polymorphs |
| EP1660456A2 (de) | 2003-08-25 | 2006-05-31 | Microbia Inc. | Quaternäre salzderivate von 1,4-diphenylazetidin-2-onen |
| WO2005021497A2 (en) | 2003-08-28 | 2005-03-10 | Microbia, Inc. | Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones |
| GB0321228D0 (en) | 2003-09-10 | 2003-10-08 | Inpharmatica Ltd | Modulating cell activity |
| EP1677803A2 (de) | 2003-09-26 | 2006-07-12 | Forbes Medi-Tech Inc. | Verfahren zur hemmung der expression von genen mit multi-arzneimittel-resistenz und hemmung der produktion von proteinen, die sich aus der expression dieser gene ergeben, und so verstärkung der wirksamkeit von chemotherapeutika zur behandlung von krebs |
| EP1522541A1 (de) | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Neue hypocholesterolemische Verbindungen |
| WO2005044256A1 (en) | 2003-10-30 | 2005-05-19 | Merck & Co., Inc. | 2-azetidinones as anti-hypercholesterolemic agents |
| WO2005042692A2 (en) | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
| ATE428411T1 (de) | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | Hdl-verstärkende kombinationstherapie-komplexe |
| ATE369335T1 (de) | 2003-11-10 | 2007-08-15 | Microbia Inc | 4-biarylyl-1-phenylazetidin-2-one |
| AU2004308332B2 (en) | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| GB0329778D0 (en) | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| ATE485267T1 (de) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
-
2006
- 2006-06-19 TW TW095121918A patent/TW200738676A/zh unknown
- 2006-06-19 US US11/455,625 patent/US7635705B2/en not_active Expired - Fee Related
- 2006-06-19 CA CA002610959A patent/CA2610959A1/en not_active Abandoned
- 2006-06-19 KR KR1020077030855A patent/KR20080021082A/ko not_active Withdrawn
- 2006-06-19 JP JP2008518276A patent/JP2008546784A/ja not_active Withdrawn
- 2006-06-19 DE DE602006010870T patent/DE602006010870D1/de active Active
- 2006-06-19 ES ES06773528T patent/ES2337727T3/es active Active
- 2006-06-19 MX MX2008000115A patent/MX2008000115A/es active IP Right Grant
- 2006-06-19 AT AT06773528T patent/ATE450526T1/de not_active IP Right Cessation
- 2006-06-19 CN CNA2006800301178A patent/CN101243072A/zh active Pending
- 2006-06-19 EP EP06773528A patent/EP1902046B1/de active Active
- 2006-06-19 AU AU2006262441A patent/AU2006262441A1/en not_active Abandoned
- 2006-06-19 WO PCT/US2006/023800 patent/WO2007001975A1/en not_active Ceased
- 2006-06-20 AR ARP060102617A patent/AR054787A1/es not_active Application Discontinuation
-
2007
- 2007-12-06 IL IL187984A patent/IL187984A0/en unknown
- 2007-12-18 ZA ZA200710968A patent/ZA200710968B/xx unknown
-
2009
- 2009-07-22 US US12/507,563 patent/US7846946B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007001975A1 (en) | 2007-01-04 |
| MX2008000115A (es) | 2008-03-18 |
| US7846946B2 (en) | 2010-12-07 |
| TW200738676A (en) | 2007-10-16 |
| EP1902046A1 (de) | 2008-03-26 |
| AR054787A1 (es) | 2007-07-18 |
| HK1121737A1 (en) | 2009-04-30 |
| CN101243072A (zh) | 2008-08-13 |
| US7635705B2 (en) | 2009-12-22 |
| ZA200710968B (en) | 2009-03-25 |
| AU2006262441A1 (en) | 2007-01-04 |
| US20070015807A1 (en) | 2007-01-18 |
| IL187984A0 (en) | 2008-03-20 |
| WO2007001975A8 (en) | 2008-01-24 |
| ES2337727T3 (es) | 2010-04-28 |
| KR20080021082A (ko) | 2008-03-06 |
| JP2008546784A (ja) | 2008-12-25 |
| DE602006010870D1 (de) | 2010-01-14 |
| US20090286830A1 (en) | 2009-11-19 |
| EP1902046B1 (de) | 2009-12-02 |
| CA2610959A1 (en) | 2007-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE450526T1 (de) | Als antagonisten von histamin h3 geeignete piperidinderivate | |
| ATE344798T1 (de) | Als histamin-h3-antagonisten geeignete indolderivate | |
| ATE494287T1 (de) | Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase | |
| DE602006015607D1 (de) | Thiazol-4-carboxamid-derivate als mglur5-antagonisten | |
| ATE452635T1 (de) | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer | |
| ATE520671T1 (de) | Pyrimidin-harnstoff-derivate als kinase-hemmer | |
| ATE521607T1 (de) | Piperidinderivate als renin-inhibitoren | |
| ATE461191T1 (de) | N-substituierte 2-oxodihydropyridinderivate als npy antagonisten | |
| ATE404564T1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| ATE448217T1 (de) | Substituierte piperidine als renin-inhibitoren | |
| ATE540936T1 (de) | Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer | |
| ATE524467T1 (de) | Neuartige aza-heterozyklen als kinase-inhibitoren | |
| DE60319813D1 (de) | 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten | |
| DE602004025258D1 (de) | Aminotriazol-verbindungen als proteinkinase-hemmer | |
| DE602006008945D1 (de) | Isochinolinderivate als inhibitoren von rho-kinase | |
| DE60320529D1 (de) | Chinolinderivate als npy antagonisten | |
| ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
| ATE414698T1 (de) | Durch 5gliedrige heterocyclen substituierte mtp- inhibierende arylpiperidine oder -piperazine | |
| ATE530545T1 (de) | Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate | |
| ATE394391T1 (de) | Indolderivate als histaminrezeptorantagonisten | |
| ATE449091T1 (de) | Substituierte triazolderivate als oxytocinantagonisten | |
| ATE370135T1 (de) | Substituierte piperidine als histamin-h3- rezeptorliganden | |
| DE602006019624D1 (de) | Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors | |
| ATE509011T1 (de) | Pyrimidinderivate als 11beta-hsd1-inhibitoren | |
| DE602005014646D1 (de) | Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |